Nancy Falotico

1.3k total citations
5 papers, 178 citations indexed

About

Nancy Falotico is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Nancy Falotico has authored 5 papers receiving a total of 178 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Hematology and 2 papers in Genetics. Recurrent topics in Nancy Falotico's work include Acute Myeloid Leukemia Research (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Nancy Falotico is often cited by papers focused on Acute Myeloid Leukemia Research (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Nancy Falotico collaborates with scholars based in United States, Australia and Israel. Nancy Falotico's co-authors include Evelyn McKeegan, Brenda Chyla, Joel Johansson, Anthony Letai, Jalaja Potluri, Rod Humerickhouse, Mack Mabry, Marina Konopleva, Daniel A. Pollyea and Rachel Kirby and has published in prestigious journals such as Blood, Cancer Research and Annals of Oncology.

In The Last Decade

Nancy Falotico

5 papers receiving 175 citations

Peers

Nancy Falotico

MB

ONCOL

HEMAT

GENET

PHEOH

Sarah Inglott United Kingdom

Lixia Ding China

Amanda R. Leonti United States

Hannah Moatti France

Ahmed Galal United States

Omar Castañeda Puglianini United States

Mary Ann Yancey United States

Valéria Bisio Italy

Bishoy Hanna Spain

Sarah Inglott United Kingdom

Nancy Falotico

92 ×0.8

MB

99 ×1.2

ONCOL

100 ×1.5

HEMAT

29 ×0.6

GENET

74 ×2.6

PHEOH

Citations per year, relative to Nancy Falotico Nancy Falotico (= 1×) peers Sarah Inglott

Countries citing papers authored by Nancy Falotico

Since Specialization

Citations

This map shows the geographic impact of Nancy Falotico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Falotico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Falotico more than expected).

Fields of papers citing papers by Nancy Falotico

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Falotico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Falotico. The network helps show where Nancy Falotico may publish in the future.

Co-authorship network of co-authors of Nancy Falotico

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Falotico. A scholar is included among the top collaborators of Nancy Falotico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Falotico. Nancy Falotico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Middleton, Mark R., Philip Friedlander, Omid Hamid, et al.. (2015). Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology. 26(10). 2173–2179. 69 indexed citations

2.

DiNardo, Courtney D., Daniel A. Pollyea, Keith W. Pratz, et al.. (2015). A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy. Blood. 126(23). 327–327. 53 indexed citations

3.

Hogdal, Leah J., Brenda Chyla, Evelyn McKeegan, et al.. (2015). Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia. Cancer Research. 75(15_Supplement). 2834–2834. 2 indexed citations

4.

Konopleva, Marina, Daniel A. Pollyea, Jalaja Potluri, et al.. (2014). A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). Blood. 124(21). 118–118. 50 indexed citations

5.

Isakoff, SJ, Nancy Falotico, Bella Kaufman, et al.. (2012). Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer. Cancer Research. 72(24_Supplement). OT2–3. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact